Explanipedia

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure Open

Robert Redd, Paolo F. Caimi, Richard C. Godby, David A. Bond, Jason T. Romancik , et al. · 2025

Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study Open

Alex F. Herrera, Stephen M. Ansell, Pier Luigi Zinzani, John Radford, Kami J. Maddocks , et al. · 2025

Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami)…

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States Open

Sudipto Mukherjee, Weichuan Dong, Aaron T. Gerds, Hetty E. Carraway, Abhay Singh , et al. · 2025

Compared with data from clinical trials, US population-level data show decreased effectiveness of hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS). We sought to identify factors associated with patterns of HMA…

180 | IMPACT OF TP53 MUTATIONS AND COPY NUMBER LOSS ON SURVIVAL OUTCOMES FOR PATIENTS WITH NEWLY DIAGNOSED LARGE B CELL LYMPHOMAS Open

Daniel J. Landsburg, Nancy Musoke, Caren Gentile, T. R. Brooks, Sunita D. Nasta , et al. · 2025

295 | EARLY MORTALITY DLBCL PREDICTION WITH AN ENHANCED R‐IPI SCORE DEVELOPED USING AN ENSEMBLE MACHINE LEARNING MODEL Open

Arun Muthiah, Ruiqing Zhao, Agrima Mian, T. R. Brooks, Allison Winter , et al. · 2025

241 | MATCHING‐ADJUSTED INDIRECT COMPARISON OF EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE VERSUS TAFASITAMAB WITH RITUXIMAB + LENALIDOMIDE IN SECOND‐LINE + FOLLICULAR LYMPHOMA Open

Julie M. Vose, Paolo F. Caimi, Yasmin Karimi, Keyan Yang, Zhijie Ding , et al. · 2025

78 | INITIAL RESULTS FROM LOTIS‐7: A PHASE 1B STUDY OF LONCASTUXIMAB TESIRINE PLUS GLOFITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) Open

Juan Pablo Alderuccio, Craig Okada, G. Crochet, Emily C. Ayers, Marie Hu , et al. · 2025

240 | EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3‐YEAR FOLLOW‐UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA Open

Kim Linton, Julie M. Vose, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan , et al. · 2025

455 | BENDAMUSTINE AS LYMPHODEPLETING CHEMOTHERAPY PRIOR TO AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA Open

Amanat Ali, Nausheen Ahmed, Sanjeevi Bharadwaj, J. Shaw, Michael Tees , et al. · 2025

CAR T-cell reality for R/R LBCL: challenges and challengers Open

Paolo F. Caimi, Craig S. Sauter · 2025

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial Open

Armin Ghobadi, Paolo F. Caimi, Jane Reese, Krishna Goparaju, Martina Di Trani , et al. · 2025

This clinical trial was funded through University Hospitals Seidman Cancer Center and Washington University School of Medicine Institutional Funds. Correlative analyses were funded in part by the European Union-Next Generation EU-NRRP M6C2…

Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study Open

Mehdi Hamadani, Paolo F. Caimi, Brian T. Hess, John Radford, Melhem Solh , et al. · 2024

These results show that Lonca is a treatment option with controllable side effects for many patients with DLBCL whose disease did not respond or came back after 2 or more previous treatments. For participants whose lymphoma completely shra…

Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary Open

Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo‐Stella, Masoud Nickaeen, Eric Jordie , et al. · 2024

While Lonca uses the CD19 target to find and destroy cancer cells, Lonca does not require a large amount of CD19 to kill tumor cells. These results mean that Lonca may be an effective treatment for patients with DLBCL, even if CD19 express…

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis Open

Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder , et al. · 2024

Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can aff…

Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice Open

Céline Gregoire, Beatriz Coutinho de Oliveira, Paolo F. Caimi, Jo Caers, J. Joseph Melenhorst · 2024

Summary Autologous chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of lymphoid malignancies, leading to the approval of CD19‐CAR T cells for B‐cell lymphomas and acute leukaemia, and more recently, B‐cell ma…

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation Open

Narendranath Epperla, Ying Huang, Amanda F. Cashen, John L Vaughn, Walter Hanel , et al. · 2024

There are limited data assessing the risk scores for primary treatment failure (PTF) in patients with classical Hodgkin lymphoma (cHL; PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE (Evaluation of Cla…

Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy Open

Chiara Tarantelli, David N. Wald, Nicolas Munz, Filippo Spriano, Alessio Bruscaggin , et al. · 2024

Antibody-drug conjugates (ADC) represent one of the most successful therapeutic approaches introduced into clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19-targeting ADC in which the antibody is conjugat…

BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation Open

Robert Stuver, Agrima Mian, Samantha Brown, Sean M. Devlin, Paolo F. Caimi , et al. · 2024

[Image: see text]

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy Open

Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Yasmin Karimi, Rajat Bannerji , et al. · 2024

Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in patients with heavily pretreat…

Supplementary Table S3 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial Open